Overview
Arpico Insurance is a Sri Lankan life and health insurer under the Arpico brand, distributing mainly individual policies and managing a Life Fund. At a market capitalisation of about LKR 1.9 billion, the stock sits near book but the most important change is earnings weakness: FY2025 group ROE printed at 0.5% and the trailing EPS is thin, leaving the shares on a stretched headline P/E despite a modest P/B. Management highlights digital enablement and disciplined costs, and governance saw fresh additions in July. The crux from here is whether the company can stabilise profitability after volatile quarterly prints through 2025 into 1Q 2026.
Price performance
The share fell 22.2% over six months and is down 6.7% in three months, broadly tracking the ASPI over that window, before edging up 2.6% this week. Over one year it is up 8.5%, lagging the ASPI’s 10.9%. The price closed at LKR 28.00, within a 52-week range of LKR 24.70 to LKR 40.00, implying mid-range positioning after a weak first half. Liquidity is thin, with a 20-day average of 632 shares, which can amplify price gaps. A beta to the ASPI of 2.13 signals outsized index-linked swings, so moves can be abrupt in either direction when market tone shifts.
Valuation
Headline valuation is demanding on depressed earnings: P/E is 233 versus a sector median 12.22. By contrast, P/B is 1.0, below the sector’s 1.22, consistent with the very low FY2025 ROE of 0.5%. The shares trade around book value per share, so the case hinges on improving returns to reconcile price with fundamentals. There is no trailing dividend, against a sector median yield of 7.4, limiting carry while investors wait for earnings normalisation. In short, today’s P/E looks optical, but without a visible profit rebound the P/B is unlikely to re-rate toward sector levels.
News and sentiment
Coverage over the past 90 days is light but relevant: 4 material items with a sentiment split of 1 positive, 2 negative and 1 neutral. Governance strengthened with the appointment of finance professional Naresh Tillekeratne to the Board, and a separate appointment to the Board Audit Committee. A June filing disclosed the profit for FY2025, which the market read negatively, and another brief filing provided limited detail. There have been no trading updates beyond the March 2026 quarter in this window and no confirmed corporate actions. Overall, tone is cautious, with governance improvements offset by a weak profit disclosure.
Financials
Latest reported quarter to 31 Mar 2026 (company basis) showed revenue of LKR 487.5 million and net profit of LKR 5.6 million, a slim net margin of 1.1%. That margin compares to 2.1% in the March 2025 quarter (group basis), highlighting a still-soft profitability profile and an imperfect like-for-like comparison due to basis differences. Through FY2025 (group), ROE was 0.5%, reflecting very low earnings relative to capital. Total equity at the FY2025 year-end was about LKR 1.7 billion. The share count was stable at roughly 66.23 million, and there were no confirmed corporate actions, so per-share moves reflect underlying profit, not dilution. Quarterly prints across 2025 were volatile, including one quarter with a loss and another with a strong net margin.
Risks
Earnings volatility is the primary risk, with swings from loss to double-digit margins in 2025 followed by a thin 1.1% net margin in 1Q 2026. Thin trading can exacerbate price gaps, and a high beta indicates heightened sensitivity to market direction rather than inherently lower risk. As a life insurer, AINS is exposed to interest rate moves, product persistency and assumptions in reserving. Regulatory and compliance complexity is rising in areas like data protection and cyber, which can add cost and operational risk. Finally, the absence of a dividend removes a buffer while investors wait for an earnings stabilisation.
Outlook
The next catalyst is the June 2026 quarter: evidence of margin repair back toward the teens seen in 4Q 2025 would support a valuation reset, while another low-single-digit margin would keep the P/E optically elevated. Sector data show life industry growth in 1Q 2026, with GWP up 24.54%, a helpful backdrop if AINS can capture share. With CBSL policy steady at 8.75%, investment yields are stable, so underwriting discipline and expense control will likely drive the profit path. Watch for clearer separation of operating performance from below-the-line items in disclosures and any sign of resumed distributions as a confirmation of earnings quality.